| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.2009.240 |
| P698 | PubMed publication ID | 20182423 |
| P2093 | author name string | Z Li | |
| P B Watkins | |||
| F A Wright | |||
| J M Macdonald | |||
| T M O'Connell | |||
| J H Winnike | |||
| P2860 | cites work | Antituberculosis drugs and hepatotoxicity | Q36628708 |
| Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury | Q37089756 | ||
| Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans | Q37363157 | ||
| Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? | Q37364425 | ||
| Glycine protection of PC-12 cells against injury by ATP-depletion | Q40651752 | ||
| An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria | Q44405516 | ||
| Hepatotoxin-induced hypercreatinaemia and hypercreatinuria: their relationship to one another, to liver damage and to weakened nutritional status | Q44603520 | ||
| Using controlled clinical trials to learn more about acute drug-induced liver injury | Q45833400 | ||
| Testing the Equality of Two Independent Binomial Proportions | Q56432197 | ||
| Orthogonal projections to latent structures (O-PLS) | Q56435041 | ||
| Susceptibility of Human Metabolic Phenotypes to Dietary Modulation | Q58045940 | ||
| Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects | Q59305041 | ||
| Influence of feeding on metabolite excretion evidenced by urine 1 H NMR spectral profiles: a comparison between subjects living in Rome and subjects living at arctic latitudes (Svaldbard) | Q60464213 | ||
| Effect of glycine on valproate toxicity in rat hepatocytes | Q72714997 | ||
| Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats | Q79801989 | ||
| Chemometrics in metabonomics. | Q30359585 | ||
| Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models | Q31137205 | ||
| Metabonomics: a platform for studying drug toxicity and gene function | Q34139125 | ||
| Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study | Q34471434 | ||
| Pharmaco-metabonomic phenotyping and personalized drug treatment | Q34515169 | ||
| Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial | Q34544702 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatotoxicity | Q1349821 |
| P304 | page(s) | 45-51 | |
| P577 | publication date | 2010-02-24 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans | |
| P478 | volume | 88 |
| Q38693004 | 21st century toolkit for optimizing population health through precision nutrition. |
| Q38191681 | Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease |
| Q35101500 | Age-related changes in the hepatic pharmacology and toxicology of paracetamol |
| Q37338124 | Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients |
| Q36669589 | Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen |
| Q37926590 | Central role of mitochondria in drug-induced liver injury |
| Q37950296 | Challenges and opportunities of metabolomics |
| Q51369690 | Circulating acetaminophen metabolites are toxicokinetic biomarkers of acute liver injury. |
| Q34915414 | Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. |
| Q28477581 | Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells |
| Q38122649 | Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics |
| Q47367156 | Dietary supplementation with cysteine prevents adverse metabolic outcomes of repeated cures with paracetamol in old rats. |
| Q33949227 | Drug-induced liver injury in older adults. |
| Q37867695 | Drug-induced liver injury: a summary of recent advances. |
| Q37294747 | Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study |
| Q46495913 | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. |
| Q33648066 | Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches |
| Q28067029 | From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine |
| Q36245131 | Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations. |
| Q28535572 | Identification of differential responses to an oral glucose tolerance test in healthy adults |
| Q42263059 | Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts |
| Q38045377 | Latest advances in predicting DILI in human subjects: focus on biomarkers |
| Q41951728 | Liver Effects of Clinical Drugs Differentiated in Human Liver Slices |
| Q38297772 | Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity |
| Q39258217 | Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI). |
| Q26829105 | Metabolomic fingerprinting: challenges and opportunities |
| Q41666681 | Metabolomics Analysis of Urine Samples from Children after Acetaminophen Overdose |
| Q54257582 | Metabolomics as a tool for personalizing medicine: 2012 update. |
| Q28831476 | Metabolomics enables precision medicine: "A White Paper, Community Perspective" |
| Q26741270 | Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health |
| Q47748333 | Metabotyping for the development of tailored dietary advice solutions in a European population: the Food4Me study |
| Q26772297 | Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications |
| Q38834940 | Nuclear magnetic resonance metabolomics and human liver diseases: The principles and evidence associated with protein and carbohydrate metabolism. |
| Q35551472 | Nutrigenomics and personalized diets: What will they mean for food? |
| Q28390150 | Nutritional lipidomics: molecular metabolism, analytics, and diagnostics |
| Q36477760 | Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice |
| Q46327411 | Paracetamol: overdose-induced oxidative stress toxicity, metabolism, and protective effects of various compounds in vivo and in vitro. |
| Q27690772 | Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives |
| Q33561982 | Patterns of acetaminophen use exceeding 4 grams daily in a hospitalized population at a tertiary care center |
| Q35842112 | PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses |
| Q34234941 | Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q28485993 | Pharmacometabolomic approach to predict QT prolongation in guinea pigs |
| Q91603932 | Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan |
| Q64389174 | Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients |
| Q37701143 | Pharmacometabolomics in Early-Phase Clinical Development. |
| Q35032056 | Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. |
| Q38124254 | Pharmacometabonomics and personalized medicine |
| Q37822760 | Pharmacometabonomics as an effector for personalized medicine. |
| Q38452107 | Pharmacometabonomics in humans: a new tool for personalized medicine |
| Q37994122 | Potential role of metabolomic approaches for Chinese medicine syndromes and herbal medicine |
| Q37771029 | Predicting and preventing acute drug-induced liver injury: what's new in 2010? |
| Q28482330 | Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum |
| Q28550555 | Predose and Postdose Blood Gene Expression Profiles Identify the Individuals Susceptible to Acetaminophen-Induced Liver Injury in Rats |
| Q45792390 | Quantitative analysis of acetaminophen and its primary metabolites in small plasma volumes by liquid chromatography-tandem mass spectrometry |
| Q38085856 | Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria |
| Q37871623 | Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools |
| Q26765518 | Role of endoplasmic reticulum stress in drug-induced toxicity |
| Q38687132 | Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity |
| Q35000102 | Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury |
| Q30810580 | Statistical HOmogeneous Cluster SpectroscopY (SHOCSY): an optimized statistical approach for clustering of ¹H NMR spectral data to reduce interference and enhance robust biomarkers selection |
| Q36599215 | Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms |
| Q39367617 | The 100 most influential publications in paracetamol poisoning treatment: a bibliometric analysis of human studies |
| Q37776403 | The Application of Metabonomics to Predict Drug-Induced Liver Injury |
| Q26772999 | The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? |
| Q33893457 | The metabolomic window into hepatobiliary disease |
| Q34347558 | The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings |
| Q37778758 | The potential of cytokines as safety biomarkers for drug-induced liver injury |
| Q58159079 | Wearing, Thinking, and Moving: Testing the Feasibility of Fitness Tracking with Urban Youth |
| Q37912165 | Xenobiotic metabolomics: major impact on the metabolome |
Search more.